US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1922 Views
-
Last post by frodo
-
- 0 Replies
- 1284 Views
-
Last post by NHE
-
- 0 Replies
- 1691 Views
-
Last post by frodo
-
- 0 Replies
- 1242 Views
-
Last post by frodo
-
- 1 Replies
- 1767 Views
-
Last post by frodo
-
- 0 Replies
- 2070 Views
-
Last post by NHE
-
- 0 Replies
- 2464 Views
-
Last post by NHE
-
- 0 Replies
- 1072 Views
-
Last post by frodo
-
- 1 Replies
- 1490 Views
-
Last post by NHE